All In Biotech

Drug Trial Radar · NCT07938814

A First-in-human (FIH), Open-label, and Multi-center Study of CS5006 in Participants With Advanced Solid Tumors

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
CStone PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.

Conditions

  • Advanced Solid Tumors

Interventions

  • CS5006Drug

    CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Dose Escalation] Maximum tolerated dose (MTD) of CS5006Time frame: Cycle 1 (Up to 21 Days)
  2. [Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006Time frame: Up to approximately 2 years
  3. [Dose Escalation] The incidence and severity of adverse events (AEs)Time frame: Up to approximately 2 years
  4. [Dose Expansion] Objective response rate (ORR) evaluated by investigators per RECIST v1.1Time frame: Up to approximately 2 years

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Macquarie University

    North Ryde, New South Wales, Australia

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.